| Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial DP Tashkin, MD Roth, PJ Clements, DE Furst, D Khanna, EC Kleerup, ... The lancet Respiratory medicine 4 (9), 708-719, 2016 | 984 | 2016 |
| Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial D Khanna, CP Denton, A Jahreis, JM van Laar, TM Frech, ME Anderson, ... The lancet 387 (10038), 2630-2640, 2016 | 665 | 2016 |
| Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis V Smith, AL Herrick, F Ingegnoli, N Damjanov, R De Angelis, CP Denton, ... Autoimmunity reviews 19 (3), 102458, 2020 | 298 | 2020 |
| Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) D Khanna, CP Denton, CJF Lin, JM Van Laar, TM Frech, ME Anderson, ... Annals of the rheumatic diseases 77 (2), 212-220, 2018 | 279 | 2018 |
| Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis MD Mayes, L Bossini-Castillo, O Gorlova, JE Martin, X Zhou, WV Chen, ... The American Journal of Human Genetics 94 (1), 47-61, 2014 | 252 | 2014 |
| Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator‐initiated, multicenter, double‐blind, randomized, placebo‐controlled trial D Khanna, C Spino, S Johnson, L Chung, ML Whitfield, CP Denton, ... Arthritis & rheumatology 72 (1), 125-136, 2020 | 207 | 2020 |
| Survival and predictors of mortality in systemic sclerosis‐associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of … L Chung, RT Domsic, B Lingala, F Alkassab, M Bolster, ME Csuka, C Derk, ... Arthritis care & research 66 (3), 489-495, 2014 | 186 | 2014 |
| Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile B Skaug, D Khanna, WR Swindell, ME Hinchcliff, TM Frech, VD Steen, ... Annals of the rheumatic diseases 79 (3), 379-386, 2020 | 134 | 2020 |
| Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS … S Bae, R Saggar, MB Bolster, L Chung, ME Csuka, C Derk, R Domsic, ... Annals of the rheumatic diseases 71 (8), 1335-1342, 2012 | 111 | 2012 |
| Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention TM Frech, D Khanna, P Maranian, EJ Frech, AD Sawitzke, MA Murtaugh Clinical and Experimental Rheumatology-Incl Supplements 29 (2), S22, 2011 | 105 | 2011 |
| Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma … KD Kolstad, S Li, V Steen, L Chung, MB Bolster, ME Csuka, CT Derk, ... Chest 154 (4), 862-871, 2018 | 98 | 2018 |
| Antinuclear antibody-negative systemic sclerosis GA Salazar, S Assassi, F Wigley, L Hummers, J Varga, M Hinchcliff, ... Seminars in arthritis and rheumatism 44 (6), 680-686, 2015 | 91 | 2015 |
| Safety and efficacy of lenabasum in a phase II, randomized, placebo‐controlled trial in adults with systemic sclerosis R Spiera, L Hummers, L Chung, TM Frech, R Domsic, V Hsu, DE Furst, ... Arthritis & Rheumatology 72 (8), 1350-1360, 2020 | 89 | 2020 |
| Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? C Bruni, T Frech, M Manetti, FW Rossi, DE Furst, A De Paulis, F Rivellese, ... Frontiers in immunology 9, 2045, 2018 | 87 | 2018 |
| Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study A Goldberg, T Geppert, E Schiopu, T Frech, V Hsu, RW Simms, SL Peng, ... Arthritis research & therapy 16, 1-12, 2014 | 86 | 2014 |
| Measuring response in the gastrointestinal tract in systemic sclerosis D Khanna, V Nagaraja, H Gladue, W Chey, M Pimentel, T Frech Current opinion in rheumatology 25 (6), 700-706, 2013 | 76 | 2013 |
| Prevalence and correlates of sleep disturbance in systemic sclerosis—results from the UCLA scleroderma quality of life study T Frech, RD Hays, P Maranian, PJ Clements, DE Furst, D Khanna Rheumatology 50 (7), 1280-1287, 2011 | 74 | 2011 |
| Multinational qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis JD Pauling, RT Domsic, LA Saketkoo, C Almeida, J Withey, H Jay, ... Arthritis care & research 70 (9), 1373-1384, 2018 | 72 | 2018 |
| The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts DH Dougherty, L Kwakkenbos, ME Carrier, G Salazar, S Assassi, M Baron, ... Rheumatology 57 (9), 1623-1631, 2018 | 71 | 2018 |
| Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population‐based study T Frech, D Khanna, B Markewitz, G Mineau, R Pimentel, A Sawitzke Arthritis & Rheumatism 62 (7), 2109-2116, 2010 | 68 | 2010 |
